Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.
Chimukangara B, Lessells RJ, Rhee SY, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, Gordon M, Makadzange T, Kiepiela P, Ramjee G, Ledwaba J, Kalimashe M, Morris L, Parikh UM, Mellors JW, Shafer RW, Katzenstein D, Moodley P, Gupta RK, Pillay D, Abdool Karim SS, de Oliveira T. Chimukangara B, et al. Among authors: ledwaba j. EClinicalMedicine. 2019 Mar 18;9:26-34. doi: 10.1016/j.eclinm.2019.03.006. eCollection 2019 Mar. EClinicalMedicine. 2019. PMID: 31143879 Free PMC article.
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L. Coovadia A, et al. Among authors: ledwaba j. Clin Infect Dis. 2009 Feb 15;48(4):462-72. doi: 10.1086/596486. Clin Infect Dis. 2009. PMID: 19133804 Free PMC article.
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
Dlamini JN, Hu Z, Ledwaba J, Morris L, Maldarelli FM, Dewar RL, Highbarger HC, Somaroo H, Sangweni P, Follmann DA, Pau AK; Phidisa II Study Team. Dlamini JN, et al. Among authors: ledwaba j. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):304-8. doi: 10.1097/QAI.0b013e3182278c29. J Acquir Immune Defic Syndr. 2011. PMID: 21694608 Free PMC article. Clinical Trial.
Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.
Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Johnston V, et al. Among authors: ledwaba j. J Infect Dis. 2014 Mar 1;209(5):711-20. doi: 10.1093/infdis/jit411. Epub 2013 Aug 13. J Infect Dis. 2014. PMID: 23943851 Free PMC article.
Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia.
Hong SY, Jonas A, DeKlerk M, Shiningavamwe A, Desta T, Badi A, Morris L, Hunt GM, Ledwaba J, Sheehan HB, Lau K, Trotter A, Tang AM, Wanke C, Jordan MR. Hong SY, et al. Among authors: ledwaba j. J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):463-71. doi: 10.1097/QAI.0000000000000509. J Acquir Immune Defic Syndr. 2015. PMID: 25564107 Free PMC article.
32 results